Showing 5931-5940 of 8887 results for "".
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- AbbVie: Rinvoq Hits AD Treat-to-Target Aims as Early as Week 2https://practicaldermatology.com/news/abbvie-rinvoq-hits-ad-treat-to-target-aims-as-early-as-week-2/2461142/Treatment with Rinvoq® (upadacitinib) 15mg or 30mg allows patients to rapidly achieve their initial three-month acceptable treatment target goal at Week 2, with consistent achievement through Week 16, results of a new analysis show. Using the framework of the recently developed evidence-based
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new
- Phase 3 Data: Sun Pharma’s Winlevi Is Safe and Effective Acne Txhttps://practicaldermatology.com/news/phase-3-data-sun-pharmas-winlevi-is-safe-and-effective-acne-tx/2461134/Results from two Phase 3 pivotal clinical trials showed favorable safety and efficacy data for Winlevi (clascoterone) cream 1% in patients with acne aged 12 years and older. The findings were presented at the American Academy of Dermatol
- Alma Launches Alma TED, CBD+ Professional Linehttps://practicaldermatology.com/news/alma-launches-alma-ted-cbd-professional-line/2461132/Alma TED, an Ultrasound-based system with a propriety Tip engineered with Impact Delivery™, offers a non-invasive, non-traumatic option to address the market's growing hair loss concerns. Alma launched the device, along with the CBD+ Professional S
- Tremfya Safe, Effective Across Broad Patient Subpopulations Through 5 Years: Analysishttps://practicaldermatology.com/news/tremfya-safe-effective-across-broad-patient-subpopulations-through-five-years-analysis/2461130/Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson can provide a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO), based on an
- Poster: Interim Data Show Safety, Efficacy of Adbry for More than Three Yearshttps://practicaldermatology.com/news/poster-interim-data-show-safety-efficacy-of-adbry-for-more-than-three-years/2461129/Interim data support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) for up to 3.5 years in adult patients with moderate-to-severe atopic dermatitis (AD). Results were shared as a
- Mark D. Kaufmann, MD, FAAD Takes the Helm at AADhttps://practicaldermatology.com/news/mark-d-kaufmann-md-faad-takes-the-helm-at-aad/2461126/Long-time Practical Dermatology® Digital Practice editor Mark D. Kaufmann, MD, FAAD, is the new President of the American Academy of Dermatology. Dr. Kaufmann, a clinical professor of the Departmen